enGene Holdings stock analysis
Want to see ENGN full AI Analyst Report?
enGene Holdings (ENGN) Stock Price & Analysis
ENGN Stock Chart & Stats
- Day’s Range
- $1.65 - $1.95
- 52-Week Range
- $1.40 - $12.25
- Previous Close
- $1.72
- Volume
- N/A
- Average Volume (3M)
- 1.53M
- Market Cap
- $115.27M
- Enterprise Value
- -$108.30M
- Total Cash (Recent Filing)
- $266.32M
- Total Debt (Recent Filing)
- $33.27M
- Price to Earnings (P/E)
- ―
- Beta
- 0.64
- Next Earnings
- Dec 23, 2026 (Est.)
- EPS Estimate
- -0.47
- Last Dividend Ex-Date
- Feb 02, 2015
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progress
FDA alignment on key elements of a planned BLA can reduce regulatory uncertainty and give the lead program a clearer development path. Combined with reported pivotal Cohort 1 results, this supports continued clinical execution and may improve the company’s ability to advance detalimogene toward commercialization.
Balance Sheet Strength
Very low leverage gives enGene greater financial flexibility than a highly indebted clinical-stage company. The relatively small debt burden can reduce financing pressure and preserve strategic options while management funds clinical development, despite the company remaining dependent on its cash resources.
Narrower Net Loss
The substantial reduction in reported net loss indicates improved loss performance relative to 2025 and could support more disciplined capital deployment. Although enGene remains unprofitable and has no revenue base, a narrowing loss profile is a constructive operating trend if it persists during continued clinical investment.
Bears Say
No Product Revenue
The absence of reported revenue means enGene has not yet demonstrated a commercial income stream to support its operations. Its financial outlook therefore remains tied to successful clinical development, regulatory approval, and eventual launch of drug candidates rather than an established recurring business.
Persistent Cash Burn
Sustained negative operating and free cash flow requires enGene to use existing liquidity or obtain additional funding to continue operations and clinical programs. Continued cash outflows can reduce financial flexibility over time, even with a relatively strong balance sheet and low current leverage.
Unproven Commercial Model
Because enGene is still clinical-stage, its potential revenue model has not yet been validated through product sales or confirmed recurring partnerships. The business must convert development programs into approved products or licensing transactions, creating material execution dependence over the next several quarters.
enGene Holdings News
Analyst Reaffirms Buy on enGene, Maintains $4 Price Target on Operational and Market Advantages for Detalimogene
Analyst Andres Y. Maldonado of H.C. Wainwright reiterated a Buy rating on enGene Holdings, retaining the price target of $4.00. Andres Y. Maldonado has given his Buy rating due to
ENGN FAQ
What was enGene Holdings’s price range in the past 12 months?
What is enGene Holdings’s market cap?
When is enGene Holdings’s upcoming earnings report date?
How were enGene Holdings’s earnings last quarter?
Is enGene Holdings overvalued?
Does enGene Holdings pay dividends?
What is enGene Holdings’s EPS estimate?
How many shares outstanding does enGene Holdings have?
What happened to enGene Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of enGene Holdings?
What is the TipRanks Smart Score and how is it calculated?
enGene Holdings Stock Smart Score
Company Description
enGene Holdings
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ronald H. W. Cooper
- Employees
- 82
- Website
- www.engene.com
- Address
- 4868 Rue Levy, Montreal, QC, H4R 2P1, CA
enGene Holdings (ENGN) Earnings & Revenues
ENGN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 6 | 13 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 1 | 0 | 11 |











